FDA approves Propeller system for use with Ellipta inhaler

The U.S. Food and Drug Administration has approved Propeller Health's platform for use with GSK’s Ellipta inhaler.
"Today, we are pleased to announce the FDA clearance of the Propeller platform for use with GSK's Ellipta inhaler," Propeller co-founder and CEO David Van Sickle said. "Inclusion of GSK's Ellipta inhaler in Propeller's digitally-guided therapy platform is an important step in our goal of modernizing the management of respiratory disease. We look forward to working closely with GSK.”
The Propeller system was designed to help patients better understand and manage their asthma and COPD. This helps with symptom improvement and outcome.
"While it is still in the early stages of development, the emerging field of digital healthcare holds great promise for respiratory medicine,” GSK head of Respiratory Research and Development Dave Allen said. “The approval of the Propeller platform for use with the Ellipta inhaler will help us understand how patients interact with the Ellipta inhaler accurately and in real-time. By exploring the benefits of sensor technology in this way, we hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trials."